Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Latest News on PHIO

Jan 16, 2025, 1:00 PM EST - 1 day ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 2 days ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 3 days ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 4 days ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 4 days ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 15 days ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 25 days ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 4 weeks ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 4 weeks ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 5 weeks ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 5 weeks ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 3, 2024, 7:45 AM EST - 6 weeks ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Nov 19, 2024, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 2 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 2 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 3 months ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 3 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 3 months ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 3 months ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 4 months ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 5 months ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 1, 2024, 8:00 AM EDT - 6 months ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Jul 12, 2024, 8:00 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 8, 2024, 8:00 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 5, 2024, 8:00 AM EDT - 7 months ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 2, 2024, 11:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Reverse Stock Split

Jun 18, 2024, 7:30 AM EDT - 7 months ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

May 28, 2024, 7:30 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 23, 2024, 5:00 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 17, 2024, 9:00 AM EDT - 8 months ago

Phio Pharmaceuticals Secures New Investor

May 15, 2024, 1:00 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

May 9, 2024, 5:25 PM EDT - 9 months ago

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Apr 30, 2024, 7:30 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

Apr 22, 2024, 1:10 PM EDT - 9 months ago

Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Apr 16, 2024, 7:30 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Apr 11, 2024, 7:30 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

Apr 3, 2024, 7:30 AM EDT - 10 months ago

National Spotlight Features Phio's Innovative RNAi Technology Platform

Apr 2, 2024, 7:30 AM EDT - 10 months ago

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Mar 13, 2024, 2:00 PM EDT - 11 months ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

Mar 6, 2024, 10:30 AM EST - 11 months ago

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Jan 31, 2024, 8:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Dec 7, 2023, 8:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

Nov 9, 2023, 4:30 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:30 AM EST - 1 year ago

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

Oct 12, 2023, 11:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Market Cap	4.34M
Revenue (ttm)	0.00
Net Income (ttm)	-10.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,093,100
Avg Vol	7,440,982
Day's Range	N/A - N/A
Shares Out	1.49M
Stochastic %K	14%
Beta	1.51
Analysts	Strong Sell
Price Target	$36.00